Evidence map›Paper›PMID 38291275›Full record

ArticleAnnals of hematology2024

Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.

Josephine Lucero, Muhned Alhumaid, Igor Novitzky-Basso, Jose-Mario Capo-Chichi, Tracy Stockley, Vikas Gupta, Aniket Bankar, Steven Chan, Andre C Schuh, Mark Minden and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Josephine LuceroDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. josephine.lucero@uhn.ca.ORCID http://orcid.org/0000-0003-4681-3536
Muhned AlhumaidKing Saud Medical City, Riyadh, Saudi Arabia.
Igor Novitzky-BassoDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Jose-Mario Capo-ChichiAdvanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Tracy StockleyDivision of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Vikas GuptaDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Aniket BankarDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Steven ChanDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Andre C SchuhDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Mark MindenDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Jonas MattssonDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Rajat KumarDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Hassan SibaiDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Anne TierensDivision of Hematology and Transfusion Medicine, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Dennis D H KimDivision of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. dr.dennis.kim@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurable residual disease (MRD) monitoring independently predicts long-term outcomes in patients with acute myeloid leukemia (AML). Of the various modalities available, multiparameter flow cytometry-based MRD analysis is widely used and relevant for patients without molecular targets. In the transplant (HCT) setting, the presence of MRD pre-HCT is associated with adverse outcomes. MRD-negative remission status pre-HCT was also associated with longer overall (OS) and progression-free survival and a lower risk of relapse. We hypothesize that the combination of disease risk and MRD at the time of first complete remission (CR1) could identify patients according to the benefit gained from HCT, especially for intermediate-risk patients. We performed a retrospective analysis comparing the outcomes of HCT versus non-HCT therapies based on MRD status in AML patients who achieved CR1. Time-dependent analysis was applied considering time-to-HCT as a time-dependent covariate and compared HCT versus non-HCT outcomes according to MRD status at CR1. Among 336 patients assessed at CR1, 35.1% were MRD positive (MRD

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteFlow CytometryHumansNeoplasm, ResidualPrognosisRecurrenceRetrospective StudiesTransplantation, HomologousAcute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationMeasurable residual diseaseRisk-adapted treatment

Identifiers

PMID38291275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.